Udenafil
Udenafil is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 3 | 3 | 6 | 1 | 1 | 14 |
| Rectal neoplasms | D012004 | — | — | — | 1 | — | 1 | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | 1 | — | 1 |
| Chest pain | D002637 | — | R07.9 | — | — | — | 1 | — | 1 |
| Microvascular angina | D017566 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | 3 | — | 1 | 5 |
| Univentricular heart | D000080039 | — | Q20.4 | 1 | 1 | 3 | — | 1 | 5 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 2 | 3 | — | — | 4 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | 2 | 1 | — | — | 2 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | — | 2 | 1 | — | — | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | 2 | — | — | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 2 | — | — | 2 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | 1 | 1 | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 1 | — | — | 1 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 1 | — | — | — | 1 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | — | — | 1 |
| Vascular dementia | D015140 | — | F01 | — | 1 | — | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | — | 1 | — | — | — | 1 |
| Sigmoid neoplasms | D012811 | — | C18.7 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | — | N19 | 2 | — | — | — | — | 2 |
| Urologic diseases | D014570 | — | N39.9 | 2 | — | — | — | — | 2 |
| Spermatogenesis | D013091 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Udenafil |
| INN | udenafil |
| Description | The drug udenafil is marketed under the trade name Zydena. It is within the PDE5 inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Like other PDE5 inhibitors, it is used to treat erectile dysfunction. Udenafil was developed by Dong-A Pharmaceutical. It has fairly rapid onset of action (peak plasma concentration after 1 to 1.5 hours), and has long duration of action (plasma half-life of 11 to 13 hours). Udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use). Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines. It has not yet been approved for use in the United States by the U.S. Food and Drug Administration.
|
| Classification | Small molecule |
| Drug class | phosphodiesterase type 5 inhibitors (PDE5) inhibitors: (PDE5) inhibitors containing a sulfonamide moiety |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 268203-93-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103849 |
| ChEBI ID | — |
| PubChem CID | 6918523 |
| DrugBank | DB06267 |
| UNII ID | L5IB4XLY36 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 496 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use